Eribulin plus or minus trastuzumab for HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding trastuzumab to eribulin improves outcomes for people with HER2-positive breast cancer that has come back or spread. It’s meant for patients whose cancer has progressed after prior HER2 and chemotherapy treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have breast cancer that is unresectable or metastatic (not fully removable) and is HER2-positive on a lab tissue test.
- Your cancer has progressed on or soon after your most recent treatment (during treatment, after, or within 6 months after finishing adjuvant therapy).
- You have had fewer than 4 prior treatment lines for metastatic/recurrent disease (not counting hormone-free or other non-metastatic adjuvant care).
- Your heart pumping ability is adequate: ejection fraction is 50% or higher.
- Your blood counts, kidney function, and liver function are within allowed ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests a combination of two drugs—eribulin (a chemotherapy) and sintilimab (an immunotherapy that helps your immune system attack cancer)—as a first treatment for women with advanced HER2-negative breast cancer that cannot be removed by surgery.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
This trial tests a chemotherapy drug called eribulin, alone or with other medicines, in people with advanced HER2-negative breast cancer that has already been treated with an antibody-drug conjugate (ADC). It aims to see if eribulin can help when standard ADC treatment has stopped working.
This trial tests a combination of two drugs, eribulin and bevacizumab, for people with advanced HER2-negative breast cancer. It aims to see how well the treatment works and why it may or may not work.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve outcomes in people with advanced triple-negative breast cancer who have already tried at least two other chemotherapies.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.